Figure 8.
TEMRA CD8 T cells from KTs exhibit enhanced purinergic P2 × 4 receptor–dependent proinflammatory and migratory responses. The potential therapeutic targets to control the migration of CD8 T cells are shown in red. ABMR, antibody mediated rejection; WORT, wortmannin; CCCP, carbonyl cyanide m-chlorophenyl hydrazone.